- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04079426
Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome
September 3, 2019 updated by: Dr. Christian Bode, University of Bonn
Innate Immunity in Acute Respiratory Distress Syndrome: A Translational Approach to Limit Inflammasome-dependent Lung Inflammation by Tetracycline
The acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure with a mortality rate of approximately 40%.
Despite advances in its supportive treatment such as lung protective ventilation or restrictive fluid management, no effective pharmacotherapy exists to treat ARDS.
Emerging preclinical data indicates that excessive activation of the inflammasome-Caspase 1 pathway plays a key role in the development of ARDS.
Tetracycline has anti-inflammatory properties via inhibiting inflammasome-caspase-1 activation.
Since not much is known about the activation of the inflammasome in clinical ARDS, the purpose of this study is i) to investigate the the inflammasome-caspase-1 activation in clinical ARDS and ii) inhibit the innate immune response of alveolar leucocytes obtained by tetracycline from patients with ARDS
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christian Bode, Dr
- Phone Number: 14119 +49228287
- Email: christian.bode@ukbonn.de
Study Locations
-
-
-
Bonn, Germany, 53127
- Recruiting
- University Hospital Bonn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants admitted to the Intensive Care Unit of the University Hospital of Bonn with an initial diagnosis of ARDS
Description
Inclusion Criteria:
- Age > 18 years
- Informed consent of the patient
- Diagnosis of ARDS for < 48 h
Exclusion Criteria:
- Age < 18 years
- Missing informed consent
- Immune therapy
- Autoimmune disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cytokine Levels in Serum and bronchoalveolar fluid
Time Frame: 1 week
|
determined by multiplex Assay [pg/ml]
|
1 week
|
Activation Status of immune cells from blood and bronchoalveolar fluid
Time Frame: 1 week
|
incubation of immune cells with tetracycline and Determination of cytokines by multiplex assay [pg/ml]
|
1 week
|
Alarmins in Serum and bronchoalveolar fluid
Time Frame: 1 week
|
Determination by western blot, qPCR or flow cytometry
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 4, 2019
Primary Completion (Anticipated)
January 1, 2021
Study Completion (Anticipated)
January 1, 2022
Study Registration Dates
First Submitted
August 29, 2019
First Submitted That Met QC Criteria
September 3, 2019
First Posted (Actual)
September 6, 2019
Study Record Updates
Last Update Posted (Actual)
September 6, 2019
Last Update Submitted That Met QC Criteria
September 3, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Dimercaprol
Other Study ID Numbers
- BOST-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Department of Health and Human ServicesNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on Sampling of Blood and bronchoalveolar lavage
-
Assistance Publique - Hôpitaux de ParisCompletedRespiratory InfectionFrance
-
Heidelberg UniversityTerminatedObstructive Lung DiseasesAustralia, Germany
-
Hannover Medical SchoolUnknownParanasal Sinus Diseases | Cystic Fibrosis | LungtransplantationGermany
-
University Hospital, Clermont-FerrandRecruiting
-
University of ZurichRecruitingCorona Virus Infection | ARDS | CoinfectionSwitzerland
-
Imperial College LondonMillennium Pharmaceuticals, Inc.CompletedLung Diseases, ObstructiveUnited Kingdom
-
Postgraduate Institute of Medical Education and...CompletedBronchoalveolar Lavaage | Diffuse Lung DiseaseIndia
-
Manchester University NHS Foundation TrustNorfolk and Norwich University Hospitals NHS Foundation TrustCompletedPulmonary SarcoidosisUnited Kingdom
-
Capital Medical UniversityUnknownLower Respiratory Tract InfectionsChina
-
Basri CakirogluCompletedCritical Illness | COVID-19 Pneumonia | Bronchoalveolar LavageTurkey